RefinedPractice
Is Rate Of Return Pricing A Useful Approach When Value-Based Pricing Is Not Appropriate?
22 March 2019
Value-based pricing (VBP) is an efficient method for pricing new drugs. Rate of return pricing could, however, be useful in two cases: treatments for ultra-rare diseases,…
Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England
20 March 2019
Estimating a cost-effectiveness threshold reflecting the opportunity cost of adopting a new technology in a health system is not easy. A new OHE report provides empirical…
HTA in Japan: Failing to Meet International Good Practice?
15 March 2019
The Japanese government has recently announced new plans to implement HTA from April 2019. The ISPOR HTA Task Force published ‘Good Practices in HTA’ in January…
Abolishing Pharmaceutical Rebates in the US? Looking at the Trade-Offs
12 March 2019
The combination of rising drug costs in the US and increasing financial stress for individual patients has triggered intense national concern. One target has come under…
Cheap and Dirty: The Effect of Contracting Out Cleaning on Efficiency and Effectiveness
6 March 2019
Research just published in Public Administration Review, co-authored by OHE’s Professor Graham Cookson, demonstrates that contracting out auxiliary public services may lower the quality of the…
The World Needs Better Drugs for TB. The Center for Global Development and OHE Have a Proposal and We Need your Feedback
5 March 2019
Innovation is a critical tool in the global fight against tuberculosis (TB), an infectious disease that primarily affects the poor and vulnerable and ranks among the…
Pricing and Paying for Cures: Early Experience with HTA of Gene Therapy in the USA
28 February 2019
In this OHE Seminar Briefing, Dr Steven Pearson, President of ICER, sets out ICER’s early experiences of using HTA to assess gene therapy in the US,…
Student Mental Health Research Network (SMaRteN): First Funding Call and Sandpit
26 February 2019
OHE is a collaborator on SMaRteN, and we’ve just announced the first funding call on “What is distinctive about student mental health?”
Recommendations for Making Outcome-based Payments a Reality in the NHS: An Application to Cancer Drugs
21 February 2019
Making Outcome-based payments a reality in the NHS authored by The Office of Health Economics, RAND Europe, King’s College London, and Cancer Research UK, and commissioned…